WONDER-02: plastic stent vs. lumen-apposing metal stent for endoscopic ultrasound-guided drainage of pancreatic pseudocysts-study protocol for a multicentre randomised non-inferiority trial

Trials. 2024 Aug 24;25(1):559. doi: 10.1186/s13063-024-08373-6.

Abstract

Background: Endoscopic ultrasound (EUS)-guided transluminal drainage has become a first-line treatment modality for symptomatic pancreatic pseudocysts. Despite the increasing popularity of lumen-apposing metal stents (LAMSs), plastic stents may resolve non-necrotic fluid collections effectively with lower costs and no LAMS-specific adverse events. To date, there has been a paucity of data on the appropriate stent type in this setting. This trial aims to assess the non-inferiority of plastic stents to a LAMS for the initial EUS-guided drainage of pseudocysts.

Methods: The WONDER-02 trial is a multicentre, open-label, non-inferiority, randomised controlled trial, which will enrol pancreatic pseudocyst patients requiring EUS-guided treatment in 26 centres in Japan. This trial plans to enrol 80 patients who will be randomised at a 1:1 ratio to receive either plastic stents or a LAMS (40 patients per arm). In the plastic stent group, EUS-guided drainage will be performed using two 7-Fr double pigtail stents. In the LAMS group, the treatment will be performed in the same way except for LAMS use. The step-up treatment will be performed via endoscopic and/or percutaneous procedures at the trial investigator's discretion. The primary endpoint is clinical success, which is defined as a decrease in a pseudocyst size to ≤ 2 cm and an improvement in inflammatory indicators (i.e. body temperature, white blood cell count, and serum C-reactive protein). Secondary endpoints include technical success, adverse events including mortality, pseudocyst recurrence, and medical costs.

Discussion: The WONDER-02 trial will investigate the efficacy and safety of plastic stents compared to a LAMS in EUS-guided treatment of symptomatic pancreatic pseudocysts with a particular focus on the non-inferior efficacy of plastic stents. The findings will help establish a new treatment algorithm for this population.

Trial registration: ClinicalTrials.gov NCT06133023 registered on 9 November 2023. UMIN000052647 registered on 30 October 2023. jRCT1032230444 registered on 7 November 2023.

Keywords: Drainage; Endoscopy; Endosonography; Mortality; Pancreatic fistula; Pancreatic pseudocyst; Pancreatitis; Randomised clinical trial; Sepsis; Stents.

Publication types

  • Clinical Trial Protocol

MeSH terms

  • Adult
  • Drainage* / adverse effects
  • Drainage* / instrumentation
  • Drainage* / methods
  • Endosonography* / methods
  • Equivalence Trials as Topic
  • Humans
  • Japan
  • Male
  • Metals
  • Multicenter Studies as Topic*
  • Pancreatic Pseudocyst* / diagnostic imaging
  • Pancreatic Pseudocyst* / surgery
  • Pancreatic Pseudocyst* / therapy
  • Plastics*
  • Stents*
  • Treatment Outcome
  • Ultrasonography, Interventional

Substances

  • Plastics
  • Metals

Associated data

  • ClinicalTrials.gov/NCT06133023